Trials / Completed
CompletedNCT01261572
Study to Find Maintenance Dose for Periodic Administration of ASP3550
ASP3550 Phase II Study - A Maintenance-Dose-Finding Study of Three-Month Depot in Patients With Prostate Cancer -
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 155 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To find effective doses of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer.
Detailed description
ASP3550 is administered periodically to patients with prostate cancer. The primary efficacy variable is the effect of ASP3550 on the maintenance of serum testosterone suppression. In addition, the safety and pharmacokinetics of ASP3550 will be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | degarelix | periodic injection |
Timeline
- Start date
- 2010-10-12
- Primary completion
- 2012-04-24
- Completion
- 2012-04-24
- First posted
- 2010-12-16
- Last updated
- 2024-10-31
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01261572. Inclusion in this directory is not an endorsement.